BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35438757)

  • 1. Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder.
    Joudrey PJ; Kolak M; Lin Q; Paykin S; Anguiano V; Wang EA
    JAMA Netw Open; 2022 Apr; 5(4):e227028. PubMed ID: 35438757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial and Nonspatial Factors Associated with Access to Medication for Opioid Use Disorder among Pregnant Women in Massachusetts.
    Joshi C; Ho Chui KK; Skeer MR; Stopka TJ
    Subst Use Misuse; 2022; 57(13):1904-1917. PubMed ID: 36219099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
    Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
    JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
    Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
    J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
    Bello JK; Xu KY; Salas J; Bedrick BS; Grucza RA
    J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
    Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
    JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attitudes toward and training in medications for opioid use disorders: a descriptive analysis among employees in the youth legal system and community mental health centers.
    O'Reilly LM; Schwartz K; Brown SA; Dir A; Gillenwater L; Adams Z; Zapolski T; Hulvershorn LA; Aalsma M
    Subst Abuse Treat Prev Policy; 2024 Jun; 19(1):32. PubMed ID: 38907286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.
    Morgan JR; Walley AY; Murphy SM; Chatterjee A; Hadland SE; Barocas J; Linas BP; Assoumou SA
    Drug Alcohol Depend; 2021 Aug; 225():108764. PubMed ID: 34051547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
    Larochelle MR; Bernson D; Land T; Stopka TJ; Wang N; Xuan Z; Bagley SM; Liebschutz JM; Walley AY
    Ann Intern Med; 2018 Aug; 169(3):137-145. PubMed ID: 29913516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-prescribing clinicians' treatment orientations and attitudes toward treatments for opioid use disorder: Rural differences.
    Brown AR; Walters JE; Harmer B; Cates L; Jones AE
    J Subst Use Addict Treat; 2023 Dec; 155():209153. PubMed ID: 37673286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
    Shastry S; Nobel I; Allen LR; Richardson LD; Vidal K; Manini AF
    Am J Emerg Med; 2022 Jan; 51():114-118. PubMed ID: 34735968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geographic variation in availability of opioid treatment programs across U.S. communities.
    Jehan S; Zahnd WE; Wooten NR; Seay KD
    J Addict Dis; 2024; 42(2):136-146. PubMed ID: 36645315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
    Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
    JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
    Sharma A; Kelly SM; Mitchell SG; Gryczynski J; O'Grady KE; Schwartz RP
    Curr Psychiatry Rep; 2017 Jun; 19(6):35. PubMed ID: 28526967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.